Q2 EPS Estimates for BBWI Lowered by Telsey Advisory Group

Bath & Body Works, Inc. (NYSE:BBWI - Free Report) - Equities research analysts at Telsey Advisory Group lowered their Q2 2026 earnings estimates for shares of Bath & Body Works in a report released on Friday, May 30th. Telsey Advisory Group analyst D. Telsey now forecasts that the company will post earnings of $0.36 per share for the quarter, down from their prior estimate of $0.42. Telsey Advisory Group currently has a "Outperform" rating and a $38.00 target price on the stock. The consensus estimate for Bath & Body Works' current full-year earnings is $3.30 per share. Telsey Advisory Group also issued estimates for Bath & Body Works' Q4 2026 earnings at $2.16 EPS, Q1 2027 earnings at $0.56 EPS, Q2 2027 earnings at $0.45 EPS, Q4 2027 earnings at $2.27 EPS and FY2027 earnings at $3.86 EPS.

Bath & Body Works (NYSE:BBWI - Get Free Report) last announced its quarterly earnings data on Thursday, May 29th. The company reported $0.49 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.02. Bath & Body Works had a net margin of 12.43% and a negative return on equity of 44.03%. The business had revenue of $1.40 billion for the quarter, compared to analysts' expectations of $1.42 billion. During the same quarter in the prior year, the company earned $0.38 earnings per share. The business's revenue was up 2.9% compared to the same quarter last year.

Other equities analysts also recently issued reports about the company. Citigroup raised their price target on Bath & Body Works from $36.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, May 20th. Robert W. Baird lifted their target price on shares of Bath & Body Works from $45.00 to $47.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Piper Sandler set a $39.00 target price on shares of Bath & Body Works and gave the stock an "overweight" rating in a research note on Thursday, May 15th. Barclays reduced their price target on shares of Bath & Body Works from $35.00 to $30.00 and set an "equal weight" rating for the company in a research report on Friday. Finally, UBS Group upped their price objective on Bath & Body Works from $32.00 to $36.00 and gave the company a "neutral" rating in a research report on Tuesday, May 20th. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $42.00.

Bath & Body Works Price Performance

BBWI stock traded up $0.45 on Monday, reaching $27.18. 5,401,101 shares of the company traded hands, compared to its average volume of 5,096,212. The firm has a fifty day simple moving average of $29.97 and a 200-day simple moving average of $33.94. Bath & Body Works has a one year low of $24.96 and a one year high of $49.20. The company has a market cap of $5.79 billion, a P/E ratio of 6.63, a price-to-earnings-growth ratio of 0.92 and a beta of 1.87.

Hedge Funds Weigh In On Bath & Body Works

Institutional investors have recently made changes to their positions in the business. Golden State Wealth Management LLC bought a new stake in Bath & Body Works during the fourth quarter valued at approximately $26,000. SRS Capital Advisors Inc. boosted its stake in shares of Bath & Body Works by 99.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 659 shares of the company's stock worth $26,000 after acquiring an additional 329 shares during the last quarter. SVB Wealth LLC bought a new stake in shares of Bath & Body Works during the 1st quarter valued at $35,000. Geneos Wealth Management Inc. increased its stake in shares of Bath & Body Works by 217.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 1,169 shares of the company's stock worth $35,000 after purchasing an additional 801 shares in the last quarter. Finally, Lindbrook Capital LLC increased its stake in shares of Bath & Body Works by 81.9% in the 4th quarter. Lindbrook Capital LLC now owns 957 shares of the company's stock worth $37,000 after purchasing an additional 431 shares in the last quarter. Institutional investors own 95.14% of the company's stock.

Bath & Body Works declared that its board has authorized a stock buyback plan on Thursday, February 27th that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's board believes its shares are undervalued.

Bath & Body Works Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 20th. Stockholders of record on Friday, June 6th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 2.94%. The ex-dividend date of this dividend is Friday, June 6th. Bath & Body Works's payout ratio is currently 21.33%.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.